Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT03328026 Enrolling by invitation - Breast Cancer Clinical Trials

Combination Study of SV-BR-1-GM With Retifanlimab

Start date: March 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, phase I/II double arm study of the SV-BR-1-GM regimen in combination with retifanlimab in patients with metastatic or locally recurrent breast cancer who have failed standard therapy. Patients will receive the SV-BR-1-GM regimen with combination immunotherapy. There will be an initial evaluation of the combination of the SV-BR-1-GM regimen with retifanlimab every 3 weeks. If this is found to be safe and well tolerated in a cohort of at least 12 patients (dose-limiting toxicities (DLTs) in less than 30% of the patients evaluated), then an expansion cohort of up to 24 patients will be treated with that combination. These will be randomized to two regimens differing in the timing of checkpoint inhibitor administration.